Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair for Drug-induced Acute Tubulointerstitial Nephritis
NCT01893658Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in Acute Interstitial Nephritis (AIN), sponsored by Mayo Clinic. Planned start Jun 2018; status: withdrawn.
02
Drugs
omalizumab
03
Conditions
Acute Interstitial Nephritis (AIN)
Beyond the preview
Go deeper on NCT01893658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01893658.